OmniAb (OABI) Cash & Equivalents Growth (1y) (2022 - 2026)

OmniAb (OABI) Cash & Equivalents Growth (1y) (2022 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 23.81%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 15.53%
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 90.42%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 17.50%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -4.13%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 71.81%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 OmniAb 260.98 Mn 211.91 Mn 14.41 Mn 166.67%

Historic Data

Download Data
DateValue
Mar 31, 2026 166.67%
Dec 31, 2025 -27.24%
Sep 30, 2025 4.78%
Jun 30, 2025 -12.09%
Mar 31, 2025 -42.85%
Dec 31, 2024 68.71%
Sep 30, 2024 28.20%
Jun 30, 2024 -0.92%
Mar 31, 2024 -16.79%
Dec 31, 2023 -51.01%
Sep 30, 2023 106,943.89%
Jun 30, 2023 13,083.91%
Mar 31, 2023 5,170.24%
Sep 30, 2022 -94.52%
Jun 30, 2022 340.43%